Q2 2016 reportOngoing BIA engagement enables our members’ voices to be heard at the highest levels. Our latest quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from April to July 2016.

In the update, you can read up on key issues for the life sciences industry such as:

The EU Referendum, the new Government and the life sciences industry – Following the EU Referendum result, the BIA has acted swiftly to position our sector at the heart of Government thinking as events and Brexit discussions continue to unfold. Find out more about the formation of the UK EU Life Sciences Steering Group, set up to oversee and manage the transition for the sector.

The political fallout from the EU referendum result ushered in a new Prime Minister sooner than many expected. The former Home Secretary, Theresa May, entered Downing Street on 13 July and quickly set about establishing a new Government with a ministerial reshuffle and rearrangement of Whitehall departments. Published alongside the quarterly update, the BIA has produced a quick briefing for members on the new Government and key ministerial appointments. It will be updated as information emerges. You can download the guide here.

May Cabinet

Changes to innovation support not slowed by Brexit – The Government is pressing ahead with the reorganisation of the UK’s research and innovation system, including bringing the operation of Innovate UK and the seven Research Councils closer together. In addition, the announcement of a £10m Biomedical Catalyst competition for 2016 is welcome news that Innovate UK and the Government are listening to the BIA’s calls for an effective innovation policy for the life sciences.

28144680336_8a00f60fc5_oBIA Parliament Day – On 7 July 2016, 35 senior representatives from the UK’s life science industry convened for the BIA’s sixteenth annual Parliament Day – a key day of engagement between BIA members and policymakers in Whitehall and Westminster.

BIA briefing paper on orphan medicinal products – In May the BIA launched a briefing paper on Orphan Medicinal Products that looked into the 15 year application of the Orphan Regulation in Europe. The paper coincided with the European Conference on Rare Diseases and Orphan Products, which was held in the UK for the first time.

BIA-MHRA joint regulatory conference 2016 – The BIA and MHRA have published a report following their sixth annual joint conference, Accelerated Development and Access to Innovative Medicines for Patients, which took place on 4 May 2016. BIA and MHRA brought together experts from across the sector to assess the state of play, discuss how the various schemes have performed, and how the NHS might respond to current innovation challenges.

Ian Hudson quote

BIA welcomes new NHS report on access to biosimilar medicines – The BIA has welcomed the recent publication of the report of the biosimilar medicines workshops hosted by NHS England in coordination with a range of national partners. The BIA has partnered with NHS England in developing this document and is a member of the National Biosimilar Medicines Programme Board, which will be considering how to prioritise and advance the proposed next steps arising from the workshops.

For details on the above topics and more, download our latest quarterly update, Influencing and Shaping Our Sector: BIA update April – July 2016.

To learn more about BIA’s policy, public affairs and regulatory affairs work, see our previous quarterly policy updates, our consultation responses, or email Zoë with any questions.